Dermacell AWM is a technologically advanced human acellular dermal matrix that is decellularized using Matracell®, a proprietary, patented, and validated processing technology.
Matracell removes a minimum of 97% of donor DNA, allowing for rapid cellular infiltration and re-vascularization. Dermacell is utilized for the treatment of chronic wounds as well as burn management and for soft tissue reconstructive procedures such as breast reconstruction.
TWO PHYSICALLY DISTINCT SIDES
When applied, the reticular side is placed against the surgical wound or the most vascularized tissue.
MATRACELL DECELLULARIZATION TECHNOLOGY
Matracell gently renders allografts acellular without compromising the biomechanical
or biochemical properties, growth factors, collagen, and elastinthat supports patient healing.
- HIV-1/2 antibody & HIV antigen
- Hepatitis B surface antigen
- Hepatitis B core antibody
- Hepatitis C antibody
- HTLV I & II antibody
- CMV IgG
No, each product is for single use only.
Each product is for single patient use only.
The products can be stored in a clean, dry environment at ambient room temperature (15-30C). There is no need for refrigeration or freezing.
No, our products do not contain any live cells.
No, our products are non-immunogenic.
- Proprietary processing using patented Matracell technology (97% donor DNA is removed) and validated sterilization methods, patented PRESERVON technology (SAL 10-6) are used to eliminate potential deleterious components of the allograft.
- The chances of graft rejection or infection is one in the million.
- However, the product should be used with caution in patients with a known intolerance towards Ofloxacin, Vancomycin, and Amphotericin B antibiotics
- Greater than or equal to 97% of DNA removed
- Intact acellular framework
- Structural support for cells
- 10-6 sterility assurance level
- Room temperature storage
- The distributor, intermediary and/or end-user clinician or facility is responsible for storing decellularized dermis under appropriate conditions prior to further distribution or implantation. Dermis must be stored at room temperature (15°C to 30°C).
- Do not freeze or refrigerate.
- Minimize excessive exposure to light and protect from excessive heat.
Complications can occur because of various factors:
- Infection – Remove DermACELL, control the infection and apply a new matrix following adequate wound bed preparation
- Detached or displaced matrix – Remove DermACELL and assess to establish the reasons for failure. Perform adequate wound bed preparation before applying a new matrix.
- Excessive inflammation/allergic reaction – Remove DermACELL and do not reapply a new matrix.
- Failure to heal/lack of effect – Reassess the wound and the patient. When the wound is not healing the matrix may be displaced and there may be an increase in wound size.
Acellular dermal matrix meshing reduces rates of postoperative seroma, hematoma, and infection and decreases drain removal time compared with non-meshed acellular dermal matrix.